

June 12, 2026

Company name:	Mitsui Chemicals, Inc. ICHIMURA Satoshi,
Name of representative:	Representative Director and President (Securities code: 4183; Prime Market of the Tokyo Stock Exchange) TAKATAMA Yoshinori,
Inquiries:	General Manager of Corporate Communications Division (Telephone: +81-3-6880-7500)

Notice Regarding the Planned Execution of Agreements to Acquire Ultradent Products, Inc.

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: ICHIMURA Satoshi; “the Company”) hereby announces that, as of June 12, 2026, it has decided that Mitsui Chemicals America, Inc. (New York; President: Antonios Grigoriou; “MCA”), one of a wholly owned subsidiary of the Company, will acquire the shares and business assets of Ultradent Products, Inc. (“Ultradent”), which engages in the development, manufacturing, and sale of dental products such as teeth whitening and dental restorative materials, through a newly established wholly owned entity (“Holding Company”), and make Ultradent a wholly owned subsidiary of MCA (the “Acquisition”), and that it plans to enter into definitive agreements in connection with the Acquisition.

1. Background and purpose of the acquisition

Our group is undertaking a transformation into a highly profitable, high-growth global specialty business by proactively investing resources and global expansion across three specialty chemicals domains: “Life & Healthcare Solutions,” “Mobility Solutions,” and “ICT Solutions.” As key priorities, we will place greater emphasis on resource investments in Life & Healthcare Solutions, which offers stable growth and ICT Solutions, which offers high growth potential and aim to achieve business growth that outpaces market growth through active utilization of M&A and partnerships.

In the Life & Healthcare Solutions domain, we will continue to drive further growth in our core businesses of vision care and agrochemicals, while establishing the medical field—where high profitability and stable growth are anticipated—as a third pillar of earnings, thereby underpinning sustainable long-term growth of the domain as a whole.

We position the oral care business as the core of our medical field, and since acquiring Kulzer Group (Germany; “Kulzer”) from Heraeus Group (Germany) in 2013, we have worked to deepen our understanding of the oral care business while improving profitability. In addition, to achieve further growth, we are strengthening our business in the Americas, the largest market in the healthcare business.

Ultradent has development and manufacturing bases in the United States and is a global leader in teeth whitening and dental restorative materials within dental material markets, with outstanding design, development, and manufacturing technologies. Meanwhile, the teeth whitening sector is expected to expand globally at a high growth rate, supported by rising awareness of oral health and aesthetics worldwide. In addition, Ultradent has established direct sales channels to dental clinics, and we believe that the acquisition will strengthen our group’s business foundation in the United States for its oral care business.

In addition, Kulzer, which is at the center of our group’s oral care business, is expanding globally with EMEA (Europe, the Middle East and Africa) as a key region, and its product portfolio is particularly strong in dental restorative materials. Kulzer and Ultradent are complementary not only in terms of their geographic footprint but also in terms of their product portfolios, and we determined that this aligns with our growth strategy for the oral care business, leading us to carry out the acquisition. Following the completion of the acquisition, we will strive to promptly achieve synergies by combining the technologies held by the Company, Kulzer, and Ultradent, and by expanding sales through cross-selling of products, thereby aiming to transform our group into a solutions provider in dental care.


2. Method of the acquisition

In connection with the acquisition, MCA intends to establish Holding Company, which will acquire the shares and business assets of Ultradent and hold, oversee and manage them. The president of MCA is a U.S.-based executive serving as Business Sector Vice President of Life & Healthcare Solutions Business Sector, and under this structure, decision making at the local level will be accelerated.

In addition, as part of post-merger integration (PMI) following the completion of the acquisition, we will seek to provide total solutions to dental professionals and patients by promoting complementary product lineups and new product development. This will be achieved by integrating our strengths in chemical technologies, Ultradent’s extensive clinical expertise and innovation-driven corporate culture, and Kulzer’s strengths in the prosthetic and restorative fields.

Furthermore, with a view to achieving these synergies at an early stage, our group will transfer the global headquarters function of the oral care business from Japan to Holding Company, which will be located in the U.S. Through this initiative, we will optimize our business operating structure and aim to become a leading company in the oral care field.

【Transaction and integration structure】



3. Overview of Ultradent

(1) Company Name	Ultradent Products, Inc.		
(2) Company Address	505 West Ultradent Drive, South Jordan, Utah 84095, U.S.A.		
(3) Representative	President and CEO Dirk Jeffs		
(4) Description of Business	Development, manufacturing and selling of dental products including teeth whitening and dental restorative materials.		
(5) Capital	10 thousand USD (as of December 31, 2025)		
(6) Year of Establishment	1978		
(7) Major shareholder and shareholding Ratio	Dr. Dan Fischer (shareholding ratio is not disclosed due to confidentiality obligations)		
(8) Relationship between the Company and Ultradent	Capital relationship: None		
	Personnel relationship: None		
	Business relationship: None		
(9) Results of operations and financial condition for the last three years (million USD)			
Fiscal Years	Fiscal year ended December 31, 2023	Fiscal year ended December 31, 2024	Fiscal year ended December 31, 2025
Consolidated Net Assets	221.7	201.0	220.5
Consolidated Total Assets	376.5	365.1	386.5
Consolidated Sales*	346.0	351.8	372.1
Consolidated Operating Income*	29.4	25.6	30.9
Attributable to owners of the parent company Net income for the current period	13.2	20.6	24.0

*Excluding revenue and operating income from discontinued operations.

4. Overview of the principal counterparties to the acquisition of shares and business assets

The principal counterparties to the acquisition of shares and business assets in connection with the acquisition are shareholders, including Dr. Dan Fischer, the founder of Ultradent. Although detailed information is not disclosed due to confidentiality obligations, there are no capital, personnel, or business relationships between the Company and the counterparties, and none of them constitutes a related party.

5. Overview of MCA

(1) Company Name	Mitsui Chemicals America, Inc.
(2) Company Address	1 North Lexington Ave, Suite 850, White Plains NY 10601, U.S.A.
(3) Representative	Antonios Grigoriou (Business Sector Vice President, Life & Healthcare Solutions Business Sector)

(4) Business	<ul style="list-style-type: none"> •Our group’s regional headquarters for the Americas •Marketing, sales and certain manufacturing of our group’s products
(5) Capital	5 millionUSD
(6) Establishment	October, 1988
(7) Major shareholders and shareholding ratio	the Company (100%)

6. Overview of Holding Company

Following the execution of the definitive agreement for the acquisition, MCA will establish Holding Company in the U.S. as its wholly owned subsidiary.

7. Number of shares to be acquired, transaction value, and shareholding before and after the acquisition

(1) Number of shares held before the acquisition	0 shares (Number of voting rights: 0 units) (Ratio of voting rights held: 0%)
(2) Number of shares to be acquired	1,318 thousand shares (Number of voting rights: 18 thousand units)
(3) Transaction value*	900 million USD
(4) Number of shares held after the acquisition	1,318 thousand shares (Number of voting rights: 18 thousand units) (Ratio of voting rights held: 100%)

*Including acquisition costs for business assets, etc. The final transaction value will be subject to customary adjustments at the completion of the acquisition, taking into account working capital, net interest-bearing debt, and other factors.

8. Schedule

(1) Date of resolution at the meeting of Board of Directors* ¹	May 13, 2026
(2) Date of decision of the Acquisition	June 12, 2026
(3) Date of execution of the definitive agreement	June 12, 2026 (scheduled)
(4) Establishment of Holding Company	September 2026 (scheduled)
(5) Date of completion of the Acquisition* ²	September 2026 (scheduled)

*¹ At the meeting of the Board of Directors, it was resolved to delegate to the management, the authority to make the final determination regarding the acquisition and the execution of related agreements, to the extent

not inconsistent with the matters approved in such resolution.

*²Completion of the acquisition is expected to occur following the establishment of Holding Company by MCA, the transfer of MCA's contractual position to Holding Company, and the receipt of all necessary regulatory approvals and completion of required filings under applicable antitrust and foreign investment laws in each relevant jurisdiction.

9. Future outlook

The impact of the acquisition on the Company's consolidated financial results is currently being reviewed. If any matters requiring disclosure arise, the Company will disclose them promptly.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
